Table 2.
Cytotoxic activity of Satureja intermedia C.A.Mey EO on human cancer cell lines.
| Concentrations (µg/mL) | S. intermedia EO | Vinblastine | ||
|---|---|---|---|---|
| % Viability | ||||
| Hep-G2 a | MCF-7 b | Hep-G2 | MCF-7 | |
| 0 | 100 | 100 | 100 | 100 |
| 1.56 | 89.33 ± 5.25 | 96.11 ± 2.01 | 74.35 ± 2.33 | 59.43 ± 0.22 |
| 3.125 | 81.11 ± 7.09 | 92.43 ± 2.11 | 58.33 ± 1.14 | 57.22 ± 1.11 |
| 6.25 | 78.83 ± 9.11 | 86.77 ± 4.29 | 51.14 ± 0.1 | 50.01 ± 3.00 |
| 12.5 | 70.13 ± 7.01 | 82.56 ± 4.61 | 38.54 ± 1.78 | 40.22 ± 4.17 |
| 25 | 66.55 ± 3.19 | 79.12 ± 7.61 | 11.19 ± 4.12 | 14.22 ± 1.01 |
| 50 | 64.11 ± 2.00 | 76.22 ± 2.11 | 9.22 ± 1.11 | 9.79 ± 2.17 |
| IC50 * | >50 µg/mL | >50 µg/mL | 6.65 µg/mL | 6.25 µg/mL |
* IC50: the sample concentration required to inhibit cancer cell proliferation by 50%; a Hep-G2: human hepatocellular carcinoma cells; b MCF-7: human breast adenocarcinoma cells; data are expressed as means ± SD.